Abstract
Daclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Humanized
-
Bradycardia / chemically induced*
-
Carcinoma, Hepatocellular / surgery
-
Cholangitis, Sclerosing / surgery
-
Daclizumab
-
Female
-
Hepatitis B / complications
-
Humans
-
Immunoglobulin G / adverse effects*
-
Immunosuppressive Agents / adverse effects*
-
Liver Cirrhosis / surgery
-
Liver Diseases / surgery
-
Liver Neoplasms / surgery
-
Liver Transplantation*
-
Male
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Daclizumab